Mon, Jul 28, 2014, 12:56 AM EDT - U.S. Markets open in 8 hrs 34 mins

Recent

% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

fludyspnea 8 posts  |  Last Activity: Jul 26, 2014 11:05 PM Member since: Apr 24, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    This news is great!!!!!!!!!

    by weightbayou Jul 26, 2014 8:39 PM
    fludyspnea fludyspnea Jul 26, 2014 11:05 PM Flag

    Agree Weight! This is another quality trial being undertaken by Celldex!

    Six large academic centers are participating: UCLA, Northwestern, Ohio State, Emory, UVA and VCU.

    Primary completion date is Sept 2015 but it likely will recruit more quickly.

  • fludyspnea fludyspnea Jul 8, 2014 4:50 PM Flag

    That study is also being sponsored by RPCI in collaboration with the NCI. It would be nice to know how enrollment in that study is progressing; hopefully it's progressing well.

    There is also a small phase 1/2 trial of CDX-301 in Low Grade Lymphoma sponsored by Joshua Brody/Mount Sinai.

    And there is also the NCI trial of CDX-1401 and Poly-ICLC with or without CDX-301 in stage IIB-IV melanoma.

    These are the 4 non company sponsored trials and there will surely be more.

  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

    Trial is being sponsored by Roswell Park Cancer Institute in collaboration with the NCI.

    I believe that more of these non company funded trials will continue to come on line particularly with 1401, 301 and 1127.

  • fludyspnea fludyspnea Jun 11, 2014 2:34 PM Flag

    Thanks Long. Another example of a response in high GPNMB expressing tumors.

    Hopefully new CDX-011 clinical trials are on the immediate horizon!

  • Reply to

    Varlilumab Trial Change

    by fludyspnea May 8, 2014 10:57 PM
    fludyspnea fludyspnea May 9, 2014 10:44 PM Flag

    Your question is not unreasonable but I disagree.

    1) The addition of another site is likely more a function of the Mount Sinai investigators wanting to offer an exciting new therapy to their patients than it is Celldex wanting to increase recruitment.

    2) Expansion of scope from B-cell malignancies to include T-cell malignancies is in my opinion an attempt to include other hematologic malignancies in this new therapeutic option.

    Remember that there have already been several impressive responses in B-cell malignancies including: "one ongoing complete response in an aggressively pretreated patient with Hodgkins disease, now with a progression free survival of nearly nine months "(this was as of Nov 2013; I hope this patient is still experiencing a complete response).

  • This isn't listed under Celldex since it is NCI sponsored. I missed it yesterday going through the clinical trial site.

    CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma

    Study began recruiting May 7. Not sure why this wasn't mentioned at the DB conference maybe since it is NCI sponsored.

    So far there are 3 centers participating in this phase 2 open label randomized trial:

    Dartmouth
    MSKCC
    Mount Sinai

    Can't wait for more studies to begin enrolling. The best part about this one is that the NCI is footing the bill

    Sentiment: Strong Buy

  • fludyspnea by fludyspnea May 8, 2014 10:57 PM Flag

    Trial just updated today. Three main changes:

    1) Hematologic Malignancies expanded to include any T-cell Malignancy (previously B-cell only).

    2) The B-cell Malignancy enrollment of the dose escalation phase is now closed

    3) Mount Sinai Medical Center in New York has been added as a 9th site.

    The addition of a new center with a dedicated immunotherapy program is definitely a positive. Joshua Brody, MD, who's speciality is lymphoma immunotherapy will be the primary investigator. I doubt a new center would be added if preliminary results were not looking promising.

    Significance of expansion to T-cell malignancies is uncertain. T-cell lymphomas are only about 15% of lymphomas so would be harder to enroll and likely why these were not included initially. My guess is that with the possible success being seen in B-cell malignancies it was elected to include the T-cell malignancies at this point.

  • Two upcoming investor conferences posted Friday on the company website:

    Deutsche Bank 39th Annual Healthcare Conference on Wednesday, May 7, 2014 at 11:20 a.m. ET at the InterContinental Hotel in Boston

    Bank of America Merrill Lynch 2014 Healthcare Conference on Wednesday, May 14, 2014 at 4:20 p.m. PT at the Encore at the Wynn in Las Vegas

    The second presentation will be 1.5 hours following the ASCO Abstract releases on May 14.

CLDX
13.57-0.50(-3.55%)Jul 25 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.